Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke [Clinical Sciences]

Conclusions— In patients with prior ischemic stroke who receive standard antiplatelet therapy, adding vorapaxar increased the risk of intracranial hemorrhage without an improvement in major vascular events, including ischemic stroke. These findings add to the accumulating evidence establishing important risks with combination antiplatelet therapy in patients with prior stroke. Clinical Trial Registration Information— http://www.clinicaltrials.gov. Unique identifier: NCT00526474.

http://stroke.ahajournals.org/cgi/content/short/44/3/691?rss=1

Source: Stroke - February 25, 2013 Category: Neurology Authors: Morrow, D. A., Alberts, M. J., Mohr, J. P., Ameriso, S. F., Bonaca, M. P., Goto, S., Hankey, G. J., Murphy, S. A., Scirica, B. M., Braunwald, E., for the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Stee Tags: Antiplatelets Clinical Sciences Source Type: research